Search results
1 company and 4 research reports found for "Zealand Pharma"
Company results
- Zealand Pharma
Zealand Pharma is a diabetes play with a solid phase III product about to report huge amounts of cli...
Sector reports
No sector reports have been found.
Research results
Zealand Pharma
French slide back
QuickView | Pharmaceutical & Healthcare | 28/07/2011The important injection device designed to deliver Lyxumia (lixisenatide) with Lantus (insulin glargine) will not now enter clinical development until...
Zealand Pharma
Germans leap forward
QuickView | Pharmaceutical & Healthcare | 16/06/2011Zealand today licensed ZP2929, a dual action GLP-1 and oxyntomodulin analogue, to Boehringer Ingelheim (BI). GLP-1 reduces glucose levels while oxynto...
Zealand Pharma
Post-prandial position
QuickView | Pharmaceutical & Healthcare | 11/04/2011Zealand’s lead programme lixisenatide (a GLP-1 agonist partnered with Sanofi-Aventis), with its 12 hour once daily profile, may be therapeutically m...
Zealand Pharma
What about Victoza?
QuickView | Pharmaceutical & Healthcare | 03/02/2011Zealand’s partner, Sanofi-Aventis, has reported that lixisenatide, its daily GLP-1 for type 2 diabetes, is non-inferior to twice daily Byetta (exena...
